Pharmaceuticals, Biotechnology and Life Sciences
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’s CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies.
Respiratory diseases biopharmaceutical specialist, Verona Pharma said Tuesday that the U.S. Food and Drug Administration has given the green light for the kick-start of a pharmacokinetic (PK) clinical trial in the U.S. for its RPL554 candidate, with the acceptance of an Investigational New Drug application (IND).
Novartis and Allergan have joined forces to conduct a Phase IIb study to test combination of a Novartis FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH).
GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, has initiated a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes (T1D).
DermTech, Inc., a player in non-invasive molecular dermatology, has entered into two collaborations with multi-national pharmaceutical companies,
OncoMed Pharmaceuticals Inc said on Monday its experimental lung cancer drug failed a mid-stage study, sending its shares tumbling 30 percent in premarket trading.
Roche has reported interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with haemophilia A and inhibitors to factor VIII.
Biostar Pharmaceuticals, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, has reported its financial results for the year ended December 31, 2016.
The legal cannabis market was worth an estimated $6.6 billion in 2016, and is projected to grow at a compound annual growth rate (CAGR) of 16% or reaching more than $24 billion by 2025.
Sensorion, a biotech company specializing in the treatment of inner ear diseases, has appointed Nawal Ouzren as the Company’s new CEO.